Bio-Thera Out-Licenses Golimumab To Russia And CIS
Represents Foray Into ‘Important Market’
With a number of next wave candidates in its pipeline, China’s Bio-Thera Solutions has licensed one of them, golimumab, to Russian player Pharmapark, ahead of a global Phase III trial later this year.
You may also be interested in...
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.